08:00 , Feb 9, 2015 |  BC Week In Review  |  Clinical News

BJI InoPlex regulatory update

Diaxonhit received CE Mark approval for BJI InoPlex test to diagnose prosthetic bone and joint infections. The company said it will launch the non-invasive multi-parameter serologic test in France on Feb. 9. Diaxonhit (Euronext:ALEHT), Paris,...
07:00 , Oct 23, 2014 |  BC Innovations  |  Cover Story

Diagnosing resistance

It might be a day late and a dollar short, but the U.S. government is finally getting around to addressing what many experts think is the big unserved need in antibiotic resistance-new diagnostics. Faster, more...
07:00 , Oct 6, 2014 |  BC Week In Review  |  Clinical News

BJI InoPlex: Pivotal trial completed enrollment

Diaxonhit completed enrollment of 470 patients, including 200 with infected prostheses, in an open-label, French validation trial of BJI InoPlex. Diaxonhit (Euronext:ALEHT), Paris, France   Product: BJI InoPlex   Business: Diagnostic   Molecular target: NA   Description: Non-invasive...